The non-pathogenic Australian rabbit calicivirus RCV-A1 provides temporal and partial cross protection to lethal Rabbit Haemorrhagic Disease Virus infection which is not dependent on antibody titres by Strive, Tanja et al.
VETERINARY RESEARCH
Strive et al. Veterinary Research 2013, 44:51
http://www.veterinaryresearch.org/content/44/1/51RESEARCH Open AccessThe non-pathogenic Australian rabbit calicivirus
RCV-A1 provides temporal and partial cross
protection to lethal Rabbit Haemorrhagic Disease
Virus infection which is not dependent on
antibody titres
Tanja Strive1,2*, Peter Elsworth2,3, June Liu1,2, John D Wright1,2, John Kovaliski2,4 and Lorenzo Capucci5Abstract
The endemic non-pathogenic Australian rabbit calicivirus RCV-A1 is known to provide some cross protection to
lethal infection with the closely related Rabbit Haemorrhagic Disease Virus (RHDV). Despite its obvious negative
impacts on viral biocontrol of introduced European rabbits in Australia, little is known about the extent and
mechanisms of this cross protection. In this study 46 rabbits from a colony naturally infected with RCV-A1 were
exposed to RHDV. Survival rates and survival times did not correlate with titres of serum antibodies specific to
RCV-A1 or cross reacting to RHDV, but were instead influenced by the time between infection with the two viruses,
demonstrating for the first time that the cross protection to lethal RHDV infection is transient. These findings are an
important step towards a better understanding of the complex interactions of co-occurring pathogenic and
non-pathogenic lagoviruses.Introduction
The prototype of the genus Lagovirus within the family
Caliciviridae is Rabbit Haemorrhagic Disease Virus (RHDV)
[1]. RHDV causes mortality rates of up to 90% in European
rabbits (Oryctolagus cuniculus), the only species susceptible
to the virus. It causes necrotizing hepatitis of the liver, severe
disseminated intravascular coagulation and multiple organ
failure, and usually kills rabbits within 72 h [2-4]. RHDV
was first reported in an Angora rabbit colony in China [5],
although recent phylogenetic analysis suggests that patho-
genic RHDV may have evolved several decades earlier, also
in Asia [6,7]. In the past 25 years RHDV has spread amongst
domestic and wild rabbits across the world, causing eco-
nomic losses to the meat industry [8] and ecological* Correspondence: tanja.strive@csiro.au
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reproduction in any medium, provided the ordamage in countries where wild rabbits are a vital part of
the ecosystem [9].
Australia heavily relies on RHDV to control overabundant
European rabbits that were introduced to the continent ap-
proximately 150 years ago and multiplied to plague propor-
tions, causing severe damage to native vegetation and
impacting on the meat and wool industry [10-12]. In 1996,
RHDV was officially approved for release as a rabbit biocon-
trol agent in Australia [10], and was very successful in redu-
cing rabbit numbers initially [13]. However, it did not kill
rabbits very effectively in some areas of Australia, and in
rabbits from these regions antibodies cross reacting to
RHDV were found [14]. This lead to the hypothesis that re-
lated endemic caliciviruses were circulating in these rabbits,
providing some level of cross protection to lethal RDHV in-
fection [15,16]. Such a virus was recently identified in wild
Australian rabbits [17] and was designated Rabbit Calicivirus
Australia 1 (RCV-A1). Evolutionary analysis suggests that
this virus arrived in Australia together with the first wild
rabbits, approximately 150 years ago [18]. Pilot infection
studies showed that RCV-A1 causes a non-pathogenictd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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partial cross protection to lethal RHDV infection [19],
confirming RCV-A1 is hindering effective RHDV-mediated
rabbit biocontrol.
RCV-A1 adds to the growing number of non-pathogenic
lagoviruses related to RHDV that are phylogenetically dis-
tinct from RHDV [20] and that have been reported from
Italy [21], France [22-24], England [25,26] and moderately
pathogenic viruses from the United States [27] and Europe
[28]. Notably, studies that experimentally tested the im-
munological cross protection to RHDV conveyed by the
non-pathogenic caliciviruses revealed disparate and partly
unexpected results. A pilot infection study conducted with
RCV-A1 resulted in 50% surviving the RHDV chal-
lenge, although only very low numbers were used in
this study (n = 4) [19]. In several earlier studies wild-
caught Australian rabbits presumed to have antibodies
to a then unidentified RCV-A1 were challenged with
RHDV and the observed protection rates varied be-
tween 36% [15], 33% [29] and 52% [14]. In contrast,
the first non-pathogenic lagovirus that was described
by Capucci et al. in Italy proved to be 100% protective
to lethal RDHV infection [21]. Surprisingly, Le Gall-
Reculé et al. did not find any cross protection provided
by a recently isolated non-pathogenic French lagovirus
[23], although this virus is genetically much more
similar to RHDV than the Australian RCV-A1. These
divergent findings underline the need to better un-
derstand both the extent and the mechanisms of
cross protection provided by non-pathogenic relatives
of RHDV.
In addition, immunological cross protection contrib-
utes to the complex interplay between host and patho-
gen, and the processes of host-pathogen co-evolution.
Australian rabbits are beginning to develop genetic re-
sistance to RHDV [30], by mechanisms that are not
completely understood. It has been shown that Histo-
Blood Group Antigens (HBGAs) on the epithelial linings
of the rabbit gastro intestinal tract act as attachment fac-
tors for RHDV [31]. HBGA’s are synthesised by the en-
zyme #1,2 fucosyltransferase, which in rabbits is encoded
by three functional genes, Fut1, Fut2, and Sec1 that have
undergone multiple events of gene conversion during evo-
lution [32]. Recent work suggests that different RHDV
strains bind preferentially to different HBGA ligands, and
rabbits expressing weaker binding HBGA phenotypes are
found with increased frequency in wild rabbit populations
following RHDV outbreaks [33,34]. Therefore, if a wild
rabbit population is partially protected from lethal RHDV
infection by immunological cross protection from a non-
pathogenic calicivirus, this may reduce the selective pres-
sure towards genetically resistant rabbits with weaker
binding HBGA phenotypes as a means to avoid lethal
RHDV infection [33].Shedding more light on the extent and mechanisms of
the immunological cross protection conveyed by the dif-
ferent non-pathogenic rabbit caliciviruses that are co-
circulating with RHDV in wild rabbit populations is
therefore vitally important to fully understand the impli-
cations for rabbit control in Australia. Conversely, such
knowledge could contribute to the selection of non-
pathogenic virus strains that could help protect endan-
gered wild rabbit populations from RHDV outbreaks in
Europe. While commercially available vaccine have
proven effective in commercial rabbitries, vaccination
campaigns in wild rabbits are economically and logistic-
ally impracticable [20].
The aim of this study was to gain better understanding
of the extent of the cross protection that previous RCV-
A1 infection can confer to lethal RHDV challenge by ex-
posing a large number (n = 46) of rabbits with RCV-A1
antibodies to RHDV. We further investigated if the cross
protection is dependent on the titres of antibodies raised
against RCV-A1 and cross reacting to RHDV. We fur-
thermore assessed if the protection rates vary when ani-
mals are experimentally inoculated with RHDV or
acquire the infection via contact transmission.
Materials and methods
Animals and experimental design
Fifty, twelve-week-old domestic rabbits were acquired
from a commercial rabbit breeding facility where RCV-
A1 was circulating and individually marked with ear
tags. Blood samples were taken at arrival (week 0), and
then at week 3, 4 and 8 and analysed for antibodies
against RHDV. One rabbit died shortly after arrival due
to unknown causes, but unrelated to infection with ei-
ther RCV-A1 or RHDV. Three of the rabbits that were
either seronegative or IgM positive to antibodies cross
reacting to RHDV at arrival were euthanazed two weeks
after arrival. Their duodenum, liver and bile were
analysed for the presence of lagoviruses using a universal
lagovirus PCR that detects both RCV-A1 and RHDV, as
described previously [17]. Male (n = 15) and female rab-
bits (n = 31) were housed separately in two group pens.
Both pens had a floor area of approximately 15 m2. Eight
weeks post acquisition 26 rabbits (9 males and 17 fe-
males) were infected orally with 500 LD50 of a commer-
cially available RHDV-preparation (Elizabeth McArthur
Agricultural Institute, Menangle, Australia) and returned
to the group-pens.
The aim of this study was to assess if cross protection
is dependent on the titres of RCV-A1-induced anti-
bodies cross reacting to RHDV, and if there is a differ-
ence depending on the infectious dose of RHDV
received. Therefore, the rabbits were divided into two
groups, one group was experimentally inoculated with a
moderate dose of RHDV (500 LD50), and the second was
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contact (Table 1), such that both the experimentally
infected rabbits and contact rabbits had high, medium
or no IgG antibody titres cross reacting to RHDV at
week 0 (Additional file 1). For the first 24 h, infected
and non-infected animals were kept separate by a divider
in the group pen to avoid low-dose infection of the con-
tact animals through inoculum-contamination on feeders
and water bottles. On the second day the dividers were re-
moved and infected and contact animals were allowed
to mix again to allow true contact infection. Through-
out the trial, rabbits had ad libitum access to oaten
hay and commercial rabbit pellets, as well as water
bottles and dishes.
Following the RHDV challenge, rectal temperatures
were monitored twice daily and body weights were
recorded on a daily basis. In addition, rabbits were
checked every four hours during the day to record the
time of death as accurately as possible. When found
dead, rectal temperatures were taken and used to extrapo-
late the time of death based on experimentally determined
post mortem temperature decay profiles (P. Elsworth, un-
published data). Where temperatures had dropped to near
room temperature (> 8 h post mortem), the time since
death (td) was calculated as time between when the rabbit
was last seen alive and found dead (Δt) minus half the dif-
ference between Δt and 8 h: td [h] =Δt - ((Δt [h]-8)/ 2). A
final blood sample was collected from each animal at point
of death, and at days 13 and 30 post RHDV challenge from
the surviving rabbits, to monitor seroconversion to RHDV.
The trial was terminated 30 days after the RHDV challenge
and all remaining rabbits were euthanazed.
In order to assess if the observed survival rates and
survival times were influenced by the duration between
the infection with the two viruses, rabbits were divided
into groups according to the time of their seroconver-
sion to RCV-A1 for additional analysis. All rabbits that
were seronegative or equivocal for RCV-A1 antibodies at
week 0, but seroconverted within the next three weeks
(n = 8) were assigned to Group 1 (< 8 weeks between the
RCV-A1 and RHDV infection). Group 2 (n = 8) contained
animals that tested positive for RCV-A1 IgM antibodies at
week 0 or 3 as well as one animal that tested negative for
RCV-A1 IgG at week 0 but positive at week 3. The time
between infections for Group 2 was estimated based on
previous observations that IgM antibodies to RCV-A1 ap-
pear from day 3 post infection (pi) and are usually detect-
able for at least 2 weeks [19,35] (and unpublished data),
the time of RCV-A1 infection of the IgM positive animals
in group two was therefore inferred to have been approxi-
mately 8–10 weeks prior to RHDV challenge. This group
also contained rabbits #20 and #50, who had anti-RCV-A1
IgM antibodies at week 3 although their serostatus at
week 0 was uncertain (Additional file 1).The third Group was formed by animals (n = 18) that
were already seropositive when purchased and that had
acquired the RCV-A1 infection at an unknown time be-
fore acquisition. The remaining animals (n = 12) that had
lost their ear tags and showed no RCV-A1 IgM at any time
were not included into analyses that required information
about their time of seroconversion to RCV-A1 (Table 1),
however they were included into analyses assessing pos-
sible correlations of serum antibody titres at the time of
challenge with survival times and survival rates.
All procedures involving animals were carried out
according to the “Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes” and
were approved by the Australian Department of Agricul-
ture, Fisheries and Forestry Community Access Animal
Ethics Committee (#CA 2008/09/303).
Detection of viral RNA
RNA was extracted using the RNEasy kit (Qiagen, Hilden,
Germany) for tissue samples, and the Invitrogen PureLink
viral RNA kit (Invitrogen, Melbourne, Australia) for serum
and bile samples, as per the respective protocols provided
by the suppliers. Established protocols were used for the
universal lagovirus RT-PCR [17], and RHDV real time
qRT-PCR [19]. RCV-A1 qRT-PCR was carried out as de-
scribed previously [36], but with primers WAU-1 1 F
(ACCCTACAACCAACACATCAGG) and WAU-1 1R
(ATGCCTGAAGCCAAAATAAACA). These primers are
highly specific to the RCV-A1 virus strain used in this
study and do not bind RHDV.
Serology
ELISAs were used for the detection of IgA, IgG and IgM
antibodies to RHDV [21,37,38] and RCV-A1 [39] as pre-
viously described. Sera were tested in duplicates, starting
at a 1:40 dilution and subsequent 4 fold dilution steps.
Sera that were only qualitatively tested to be either sero-
positive or negative were only analysed at a 1:40 and
1:160 dilution, also in duplicates. As the isotype ELISAs
for the two viruses are known to cross react to various
degrees, a more specific competition ELISA (cELISA) for
RHDV and a specific blocking ELISA for RCV-A1 [40]
were also used, starting at a 1:10 dilution with subse-
quent 4 fold dilution steps.
Results
Several attempts were made to purchase 50 seronegative,
12 week old un-vaccinated rabbits from vaccinated does.
At the time the trial was conducted, no RCV-specific
ELISAs was available, therefore assays originally devel-
oped for RHDV were used to assess the antibody status
of the animals. The first batch was unsuitable as almost
all rabbits had very high anti-RHDV antibody titres, indi-
cating exposure to RHDV at a young age and subsequent
Table 1 Experimental groups, mortality rates, survival times and fever responses of the 46 rabbits subjected to RHDV
challenge following previous RCV-A1 exposure
ID Sex Inoculation Survival Survival time [d] Adjusted survival time [d]* Fever** Duration of fever [h] ***
Group 1
< 8 weeks between RCV-A1 and RHDV infection
18 m infected Y Y
11 f contact Y N
40 f contact Y Y
7 m infected N 8.8 Y 41.0
29 m infected N 9.9 Y 5.0
31 f infected N 2.6 N
37 m infected N 11.4 Y 15.0
36 m contact N 12.2 9.8 Y 13.0
Group 2
8-10 weeks between RCV-A1 and RHDV infection
25 f contact Y Y
20 F infected N 10.5 Y 14.0
38 m infected N 8.5 N
50 f infected N 4.5 Y 14.5
28 m contact N 10.4 8.0 Y 15.0
39 m contact N 12.2 9.8 Y 4.5
44 f contact N 9.9 7.5 Y 15.0
47 f contact N 7.0 4.6 Y 22.0
Group 3
>10 weeks between RCV-A1 and RHDV infection
32 f infected Y Y
2 f infected N 4.5 Y 14.5
3 f infected N 3.4 Y 2.3
4 f infected N 2.6 Y 7.5
6 m infected N 7.4 Y 16.0
12 f infected N 4.4 Y 5.3
15 f infected N 4.6 Y 15.8
16 m infected N 7.3 Y 14.0
17 m infected N 8.3 Y 6.5
19 m infected N 3.2 Y 3.5
21 f infected N 2.5 Y 14.0
24 f infected N 2.2 N
8 m contact N 7.0 4.6 Y 5.0
23 f contact N 6.1 3.7 Y 4.5
26 m contact N 6.2 3.8 Y 9.0
27 m contact N 9.3 6.9 Y 12.0
33 f contact N 11.0 8.6 N
45 f contact N 4.2 1.8 Y 6.5
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Table 1 Experimental groups, mortality rates, survival times and fever responses of the 46 rabbits subjected to RHDV
challenge following previous RCV-A1 exposure (Continued)
Rabbits with unknown infection history
30 f infected Y N
10 f infected N 6.2 Y 6.5
14 f infected N 2.8 Y 11.5
35 f infected N 9.5 Y 32.0
48 f infected N 9.7 Y 11.0
49 f infected N 4.0 Y 3.0
1 f contact N 7.8 5.4 Y 12.0
5 f contact N 7.7 5.3 Y 9.5
34 f contact N 15.8 13.4 N
42 f contact N 6.7 4.3 Y 9.5
43 f contact N 4.7 2.3 N
46 f contact N 5.2 2.8 Y 5.0
Surviving animals are shown in bold italics.
*Adjusted survival time is −2.4 days for the contact infected animals.
** Temperature >40.5°C. *** Time between recorded onset of fever and death.
Strive et al. Veterinary Research 2013, 44:51 Page 5 of 11
http://www.veterinaryresearch.org/content/44/1/51seroconversion. The second batch had a high proportion
(approx 60%) of rabbits with cross reactive antibodies to
a putative benign virus, as inferred using the methods
described by Cooke et al. [38]. However, as it was not
known which RCV-A1 strain had caused seroconversion
in these rabbits, this cohort of rabbits was equally un-
suitable. The third group of 50 rabbits also had anti-
bodies cross reacting to RHDV, however 17 animals
were still seronegative, and one had IgM antibodies cross
reacting to RHDV, indicating that a benign virus infection
was currently circulating in the colony. This final group of
rabbits was then used to study the effects on RHDV infec-
tion in a colony naturally infected with RCV-A1.
Three of the rabbits that were either seronegative or
had IgM antibodies cross reacting to RHDV at arrival
(#13, #22 and #41) were euthanazed at week 2 and their
duodenum, liver and bile analysed for the presence of
lagoviruses in an attempt to isolate the circulating RCV-
A1 strain. One rabbit (#22) tested positive in the PCR,
indicating an active infection with a previously unknown
RCV-A1 strain. The new strain was designated RCV-A1
WAU-1. Its relationship to the originally published
strain MIC 1–4 [17] has been described elsewhere [18].
One rabbit (#9) died shortly after arrival due to un-
known causes, but unrelated to infection with either
RCV-A1 or RHDV, as no viral RNA for either virus
could be detected in the duodenum or liver, respectively.
At the time of arrival (week 0), 14 of the 46 experi-
mental rabbits tested negative or equivocal in all three
RHDV ELISAs (IgG, IgM and cELISA), and all except 5
developed antibodies cross reacting to RHDV within
8 weeks following arrival. As soon as specific ELISAs for
RCV-A1 were available [39,40], the sera were re-analysed. Eight of the 46 animals were seronegative or
equivocal for RCV-A1 IgG, IgA and IgM at week 0, and
by week 4 all rabbits had seroconverted to RCV-A1
(Additional file 1). Unfortunately, 14 rabbits in the fe-
male group had lost their ear tags on the first day, after
the initial blood sample was collected. Numbers were re-
assigned to these animals according to their bodyweights,
however as we could not be entirely certain that the num-
bers were re-assigned correctly, no serology data is avail-
able for week 0 for these animals.
Eight weeks post acquisition, 26 of the rabbits were
perorally challenged with RHDV (Table 1) and placed
back into the group pens, so that the remaining rabbits
could acquire the infection via contact. The overall sur-
vival rate was 13% (6 of 46), and three of the survivors
had received RHDV via direct inoculation and three via
contact infection. Fever was detected in 83% of all rab-
bits (38/46), with 85% (34/40) of the non-survivors and
67% (4/6) of the surviving rabbits showing temperatures
above 40.5°C. The time to onset of fever varied greatly
between individuals, the average time between the first
detection of fever and death of the animals however was
consistently short (11.6 ± 8 h (Mean ± SD)) (Table 1).
Five of the six surviving rabbits seroconverted to
RHDV at the end of the trial (Table 2), as indicated by
high titres in the RHDV cELISA. One rabbit (#11)
avoided infection with RHDV. The serum of this rabbit
showed medium titres in the RHDV IgG ELISA, how-
ever in the absence of a positive RHDV c-ELISA, IgM
and IgA result, the IgG titres are likely to be RCV-A1
antibodies cross reacting in the RHDV IgG ELISA. This
rabbit also had no detectable fever response. Rabbit #30
also showed no fever, however this rabbit was just
Table 2 Serology (RHDV only) of rabbits surviving the RHDV challenge
ID Sex Inoculation
Weight
loss*
Antibodies to RHDV RHDV copies/μl bile
IgM IgA IgG cELISA
13 dpc 30 dpc 13 dpc 30 dpc 13 dpc 30 dpc 13 dpc 30 dpc 30 dpc
18 m infected Y + – + + > 40960 > 40960 > 640 > 640 4.11E + 03
32 f infected Y + + + + > 40960 > 40960 > 640 >640 1.55E + 04
40 f contact N + + + + D > 40960 320 > 640 5.23E + 04
25 f contact N – – – D 40 > 40960 20 > 640 2.07E + 01
30 f infected N – – – + 1280 5120 – 160 1.70E + 01
11 f contact N – – – – – 1280 – – –
Titres are expressed as the reciprocal dilutions at which the sera tested positive.
* Weight loss >10%, dpc = days post RHDV challenge, – = negative, + = positive.
D, Doubtful.
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lenge (dpc), (Table 2). As temperatures were not moni-
tored regularly beyond 13 dpc, a possible fever episode
may therefore have not been detected in this rabbit. Of
the six surviving rabbits two (#18 and #32) showed tem-
porary weight loss (> 10% but < 20%) following their fever
episode; these were the only two cases of weight loss >
10% of all 46 rabbits in this experiment. These two ani-
mals also had a clear, highly viscous mucous discharge
from the rectum for one day following their fever episode.
Unexpectedly, no correlation was observed between sur-
vival rates or survival times and serum antibody titres at the
time of RHDV challenge. Pearson’s Product Moment Cor-
relation revealed low but insignificant levels of negative
correlation (RHDV-IgG: t = −1.54, p = 0.1319; RCV-A1-IgG:
t =−1.4, p = 0.1696; RCV-A1-IgA: t = −0.914, p = 0.3667
and RCV-A1-bELISA: t = −0.568, p = 0.5737). Similarly,
there was no correlation between survival rates and any of
the antibody titres (Chi-Squared test, data not shown).
Notably, the average survival times of all rabbits that died
were unusually high, 7.1 days ± 3.3 (Mean ± SD). Survival
times for contact-infected rabbits were longer (8.4 days ±
3.1 (Mean ± SD)) compared to experimentally inoculated
rabbits (6.0 days ±3.1 (Mean ± SD)). This 2.4 day average
difference reflects the delay in acquiring the infection from
the infected rabbits that were shedding virus.
Both the infected as well as the contact animals died in
two cohorts. The first cohort died between day 2 and 4 in
the infected animals and day 4 to 7 in the contact animals.
The second cohort died between day 7 to 11 in the in-
fected, and day 9 to 12 in the contact animals, respectively.
When the survival times for the contact animals were
corrected by the average time delay it took them to acquire
the infection (−2.4 days), a clear biphasic pattern was ob-
served. Notably, the animals that died in the second cohort
showed no signs of prolonged disease, but appeared
healthy until they suddenly developed a fever and died.
A high proportion of rabbits that had been seronega-
tive to either RHDV or RCV-A1 when purchased andsubsequently seroconverted within the following 8 weeks
died in the second wave. This prompted us to investigate
if the time between the infections with RCV-A1 and
RHDV had an influence on survival rates and survival
times, and animals were grouped according to the time
between the two infections (Figure 1 and Table 1). In the
group of the recently seroconverted animals (< 8 weeks
between infections of RCV-A1 and RHDV) 3 of 8 rabbits
survived (38%) and the animals in this group that did
not survive showed prolonged survival times, with a me-
dian survival time of 9.9 days. The median survival time
in the second group of animals with 8–10 weeks be-
tween infections with the two viruses was 8.0 days, and
only one rabbit survived (13%). In comparison, median
survival time in animals with a mature immune response
in group three was 4.4 days, and in this group too only
one animal survived (6%). In the Kaplan Meier survival
analysis, the Logrank test was highly significant between
group 1 and group 3 (p = 0.002) and significant between
group 2 and group 3 (p = 0.038), but not significant be-
tween group 1 and group 2.
All rabbits that succumbed to RHDV infection had
high levels of RHDV RNA in their bile (105 to109 copies
per microliter) as determined by qRT-PCR, confirming
RHDV as the likely cause of death (data not shown). Of
the six surviving rabbits three had moderate viral loads
of RHDV in the bile, while rabbits #25 and #30 had very
low amounts of viral RNA just above the detection
threshold, and rabbit #11 had no detectable RHDV RNA
in the bile (Table 2). Trace amounts of RCV-A1 RNA
just above the detection limit (1.4 × 101 copies per
microliter) were detected in the bile of rabbit #37 (data
not shown), all other rabbits tested negative for RCV-A1
at time of death or euthanasia.
Discussion
The most surprising finding of this study was that the
partial protection provided by RCV-A1 to lethal RHDV
infection does not depend on the titres of antibodies
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Figure 1 Kaplan Meier survival analysis of rabbits challenged with RHDV. Analysis was carried out using the SigmaPlot software version
12.3. S indicates survival until 30 days post RHDV challenge when the rabbits were euthanazed.
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results obtained in previous pilot infection studies,
where the survival rate following RCV-A1 infection was
50%, and the surviving animals had higher antibody
titres cross reacting to RHDV compared to the non-
survivors [19]. However in that study only a small num-
ber of animals was used (n = 4). The data presented here
show that the titres of serum antibodies both specific to
RCV-A1 and cross reacting to RHDV are poor predictors
for survival.
Instead, our results indicate that the timing of the
RCV-A1 infection is likely to play a major role in the
outcome of an RHDV challenge. There was a marked
difference in the survival rates and survival times de-
pending on the time between RCV-A1 and RHDV infec-
tion. As it was not known when the rabbits that were
already seropositive at week 0 had acquired their RCV-
A1 infection and serum samples were only collected at
week 3, 4, and 8, it was only possible to assign the rab-
bits to three groups (Group 1: < 8 weeks; Group 2: 8–
10 weeks and Group 3: > 10 weeks). Our results show
that Group 1 rabbits with no more than 8 weeks be-
tween infections with the two viruses had the highest
survival rates (38%) and longest survival times (median
9.9 days). Protection rates decreased to 13% in Group 2,
while the survival times in this group were still unusually
long with a median of 8 days. In contrast, for Group 3
rabbits with a mature immune response to RCV-A1 and
at least 10 weeks between infections with the two vi-
ruses, there was no detectable protective effect against
lethal RHDV infection. Survival rates of 6% and median
survival times of 4.4 days are comparable to previous re-
ports describing RHDV infections in naïve rabbits [2].The temporal nature of the cross protection observed
for RCV-A1 may help to explain the wide variations de-
scribed for protection rates that the various non-
pathogenic caliciviruses provide to RHDV challenge.
Capucci et al. described complete protection (16/16 sur-
vived) when rabbits were challenged with RHDV, 24 days
after infection with the Italian RCV [21]. Fifty percent
protection (2/4 survived) was observed when rabbits
were challenged with RHDV 24 days after infection with
the Australian RCV-A1 [19] (and Table 3), and this re-
duced protection rate was initially ascribed to the lower
degree of genetic relatedness and amino acid homologies
to RHDV. Interestingly, Le-Gall and colleagues found no
protection from RHDV challenge (1/15 survived) follow-
ing previous infection with a recently discovered French
non-pathogenic virus strain, although this European iso-
late is genetically more closely related to RHDV than
RCV-A1 [23]. However, the rabbits subjected to RHDV
challenge in their study were deliberately selected to ex-
hibit high antibody titres cross reacting to RHDV, indi-
cating mature antibody responses. Indeed, several of
their rabbits had already been seropositive when ac-
quired 3 weeks prior to challenge [23]. Our findings sug-
gest that the window of heightened resistance to lethal
RHDV infection may have been missed in their study.
Future studies investigating the interference of patho-
genic and non-pathogenic lagoviruses should take into
account the time between infections as an important
contributing factor to the varying degrees of cross
protection.
As the timing of previous RCV-A1 infection appears
crucial for the outcome of subsequent RHDV challenge,
an accurate estimate of overall protection rates conveyed
Table 3 Summary of experiments assessing the level of cross protection to lethal RHDV infection provided by RCV-A1
Study No. Protection rate N RCV-A1 infection Time post RCV-A1
infection
RHDV challenge Reference
1 52% 11/21 Natural infection Unknown One dose 1000 LD 50, IM [14]
2 36% 22/61 Natural infection Unknown One dose 1500 LD 50, PO [15]
3 33% 25/77 Natural infection Unknown One dose 1500 LD 500, PO [29]
4 50% 2/4 Experimental
infection
4 weeks One dose 500 LD 50, PO [19]
5a 38% 3/8 Natural infection < 8 weeks One dose 500 LD 50, PO and/or continuous
exposure (contaminated environment)
This report
5b 13% 1/8 Natural infection 8 - 10 weeks One dose 500 LD 50, PO and/or continuous
exposure (contaminated environment)
This report
5c 6% 1/18 Natural infection > 10 weeks One dose 500 LD 50, PO and/or continuous
exposure (contaminated environment)
This report
IM, Intra muscular, PO, Peroral.
Strive et al. Veterinary Research 2013, 44:51 Page 8 of 11
http://www.veterinaryresearch.org/content/44/1/51by RCV-A1 is difficult to make. In addition, our data
and previously published observations suggest that a var-
iety of factors, such as the dose of RHDV, may play an
additional role in the outcome of RHDV challenge.
Table 3 provides a comparison of the current results
with previously published data on experimental RHDV
challenges of rabbits that were either known to be previ-
ously infected with RCV-A1, or inferred to be RCV-A1
positive due to antibodies cross reacting to RHDV. Pro-
tection rates of 33% to 52% were observed in animals ex-
perimentally infected with one dose of RHDV, ranging
from 500 to 1500 LD50, applied via the PO or IM route
(Table 3, study 1–4) [14,15,19,29]. In contrast, the
current study (Table 3, study 5a, 5b and 5c) was
conducted as a pen trial where rabbits were housed in
large groups, and were both experimentally infected and
acquired the infection via contact. It has been shown
that high amounts of RHDV-RNA can be detected in
rabbit faeces shortly before they die [19], and it is there-
fore likely that in this environment, over time, rabbits
were exposed to continuously increasing quantities of
virus due to virus shed by animals that succumbed to
the challenge. In this trial, water dishes in particular ap-
pear to be a likely source of continuous exposure, as all
rabbits used them and, although the water was changed
daily, they were heavily soiled with faecal material.
It is unclear at this stage if the rabbits with the un-
usually long survival times avoided infection or disease.
For example, rabbits #7, #17, #20, #37, #38 and #48 died
between days 8 and 11 pi. As these animals were in the
group of experimentally infected animals, the exact time
between experimental infection and death was known.
From day 3 post challenge onwards, these animals
should have had a developing antibody response to
RHDV. No increases in antibody titres reacting to
RHDV were detected in these animals at the time of
death (data not shown), however the viral load in theserum and bile was very high (109 to 1011 and 105 to 109
RNA copies/mL, respectively) as determined by qRT-
PCR (data not shown). It is possible that this high
viremia neutralised moderate titres of early serum anti-
bodies, resulting in negative ELISA results, although a
successful adaptive response to RHDV usually results in
effective clearance of infection. Alternatively, the initial
experimental infection was unsuccessful and the rabbits
acquired the virus later from the contaminated environ-
ment. Mucosal antibodies may have played a role in
avoiding the infection but were not assessed in this
study.
More research is needed to better understand the im-
munological mechanisms responsible for the temporal
nature of the cross protection. Short-term elevation of
non-specific innate immune mechanisms following RCV-
A1 infection may lead to increased levels of infectious dis-
ease resistance in general [41]. Alternatively, more mature
immune responses to RCV-A1 may be less protective to
RHDV, due to affinity maturation. The selection of B-cells
for production of antibodies with a higher affinity to the
antigen (in this case RCV-A1) would lead to antibodies
that are less cross reactive and thus possibly less protective
to RHDV. However, the observation that antibody titres
cross reacting to RHDV did not correlate with survival
time or survival rates argues against this explanation.
Cellular immune mechanisms, which are known to be
transiently elevated following infection, may also play an
important role [41]. The S domain of the capsid protein
VP60 that forms the inner shell of the viral particle [42]
is highly conserved amongst lagomorph caliciviruses.
RHDV and RCV-A1 have 93% amino acid identity in
their inner shell domains, but only 73% amino acid iden-
tity in the antigenic P2 domains. It is likely that some
antigens that are presented as MHC-I complexes are
derived from the conserved S-domain of the capsid pro-
tein VP60 or from other non-structural proteins. The
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RHDV infected cells and contribute to temporary sup-
pression of productive RHDV infection, resulting in in-
creased survival times. In some cases the infection may
be slowed down sufficiently for the rabbit to develop a
strong adaptive immune response specific to RHDV,
leading to clearance of infection and ultimately survival.
Similar mechanisms have been suggested for Influ-
enza virus, where CD8+ T-cell responses following
natural infection with Influenza A/H3N2 can induce
heterosubtypic protection to avian influenza A/H5N1 [43].
The importance of T-cell responses in the protection
from lethal RHD has also been discussed in the context
of RHDV-vaccines, using RHDV specific antigens. Protec-
tion from VP60 expressed by a recombinant canarypox
virus [44] or a recombinant ORF virus [45] to lethal
RHDV was similarly independent from the vaccine in-
duced antibody titres, and it was suggested that T-cell me-
diated immunity plays an important role [45]. However,
commercial vaccines against RHDV that are based on
inactivated, replication incompetent virus are effective in
protecting rabbits against lethal RHD, and similarly re-
combinant VLPs also provide effective protection [46], al-
though it has been demonstrated that VLPs alone are not
effective in promoting the priming of naïve T-cells [47,48].
In addition, another study shows that adoptive transfer of
polyclonal RHDV-positive serum can prevent lethal RHD
in susceptible adult rabbits [49]. Future studies are clearly
warranted shedding more light into the respective parts
that cellular immunity, antibodies, but also immunogenet-
ics [50] play in the protection and cross protection from
lethal RHDV infection.
An additional intriguing result of this infection study
was that it proved difficult to source seronegative rabbits
that were devoid of antibodies cross reacting to RHDV
due to a previous infection with benign calicivirus. Simi-
lar to murine norovirus, a calicivirus infecting mice that
is non-pathogenic in the immunocompetent host and
that was shown to be highly prevalent in scientific
mouse breeding facilities tested [51], RCV-A1 may also
be widespread amongst commercial rabbit breeding col-
onies. Non-pathogenic lagoviruses have been reported in
European rabbitries [23], and more systematic testing of
Australian rabbitries is clearly warranted to assess the
prevalence of RCV-A1 in rabbits bred both for scientific
purposes and for meat. Rabbit colonies may serve as a
reservoir for RCV-A1, and transporting farmed rabbits
or depositing soiled bedding material outside the breed-
ing facilities is a potential mechanism facilitating the
spread of RCV-A1.
The findings presented here have potentially important
implications for rabbit biocontrol in Australia. The tem-
poral nature of the cross protection conveyed by RCV-
A1 indicates that there may be a window of opportunityfor RHDV to work effectively as a biocontrol agent, pro-
vided that RCV-A1 is not present throughout the year.
Studies are therefore needed to determine the infection
dynamics and seasonal occurrence of RCV-A1 in Australia.
In contrast, if non-pathogenic caliciviruses were to be con-
sidered as natural vaccines to RHDV in countries where
rabbits are a valued wildlife species [9], the timing of the
release of such strains would be crucial to ensure max-
imum benefits to biodiversity conservation.
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